BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...products contributing to the shortfall. Sales of Avastin...
BioCentury | Oct 8, 2020
Finance

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

...corporate affairs, market access and channel management and commercialization of drugs such as Herceptin trastuzumab and Avastin...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...Tyvyt sintilimab plus Byvasda, a biosimilar of Avastin...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...tiered double-digit royalties. China’s National Medical Products Administration is reviewing a BLA for the biosimilar of anti-VEGF mAb Avastin...
BioCentury | Jul 16, 2020
Regulation

July 15 Quick Takes: Early access in U.K. for Alnylam RNAi; plus Verrica, CytoDyn, J&J and Roche

...atelizumab failed to improve progression-free survival in newly diagnosed advanced ovarian cancer when added to Avastin...
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...Products Administration announced a pair of approvals Friday. The agency approved Byvasda, a biosimilar of Avastin...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

...21 mutations. Cyramza is a VEGFR-2 antagonist and Tarceva is an EGFR-targeting tyrosine kinase inhibitor. Tecentriq-Avastin...
...approved for HCC The Genentech Inc. unit of Roche said FDA approved Tecentriq atezolizumab plus Avastin...
...in patients who haven’t received prior systemic therapy. Tecentriq is a mAb against PD-L1 and Avastin...
BioCentury | May 15, 2020
Product Development

May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX

...cancer cohort ImmunoGen Inc. (NASDAQ:IMGN) said a combination of its antibody-drug conjugate mirvetuximab soravtansine plus Avastin...
...the ORR was 43%. FORWARD II is evaluating combinations of the ADC targeting FOLR1 with Avastin...
BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

...Co. Inc. (NYSE:MRK) said FDA approved an sNDA for their PARP inhibitor Lynparza olaparib plus Avastin...
...fallopian tube, or primary peritoneal cancer. The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) markets Avastin...
BioCentury | Apr 24, 2020
Product Development

April 23 Quick Takes: Hansoh, NiKang partner for antiviral; plus Jakafi, Avastin, EpimAb-QIMR, ProThera-Takeda

...62% overall response rate (ORR) compared with 39% for best available therapy (p<0.001). Low dose Avastin...
...Ophthalmology article , the Pediatric Eye Disease Investigator Group (PEDIG) reported that low doses of Avastin...
...JAK-2 - Janus kinase-2 VEGF - Vascular endothelial growth factor BioCentury Staff Avastin, bevacizumab (RG435, Anti-VEGF antibody, R435) Jakavi...
Items per page:
1 - 10 of 1691